BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 29138665)

  • 1. [Epidemiological profile of uropathogenic enterobacteria producing extended spectrum beta-lactamases].
    Sbiti M; Lahmadi K; Louzi L
    Pan Afr Med J; 2017; 28():29. PubMed ID: 29138665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recent evolution of the epidemiological profile of extended-spectrum β-lactamase producing uropathogenic enterobacteria in Marrakech, Morocco].
    El Bouamri MC; Arsalane L; Kamouni Y; Berraha M; Zouhair S
    Prog Urol; 2014 Jun; 24(7):451-5. PubMed ID: 24861685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-Spectrum beta (β)-Lactamases and Antibiogram in Enterobacteriaceae from Clinical and Drinking Water Sources from Bahir Dar City, Ethiopia.
    Abera B; Kibret M; Mulu W
    PLoS One; 2016; 11(11):e0166519. PubMed ID: 27846254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral treatment options for patients with urinary tract infections caused by extended spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
    Raja NS
    J Infect Public Health; 2019; 12(6):843-846. PubMed ID: 31176606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current antibiotic resistance profile of uropathogenic Escherichia coli strains and therapeutic consequences].
    El Bouamri MC; Arsalane L; Kamouni Y; Yahyaoui H; Bennouar N; Berraha M; Zouhair S
    Prog Urol; 2014 Dec; 24(16):1058-62. PubMed ID: 25310915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergency Department Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Many Patients Have No Identifiable Risk Factor and Discordant Empiric Therapy Is Common.
    Frazee BW; Trivedi T; Montgomery M; Petrovic DF; Yamaji R; Riley L
    Ann Emerg Med; 2018 Oct; 72(4):449-456. PubMed ID: 29980462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
    Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
    Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of ertapenem and other antimicrobials against ESBL-producing enterobacteria isolated from urine in patients from Madrid.
    Tamayo J; Orden B; Cacho J; Cuadros J; Gomez-Garces JL; Alos JI
    Rev Esp Quimioter; 2007 Sep; 20(3):334-8. PubMed ID: 18080031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Bahrain.
    Bindayna KM; Senok AC; Jamsheer AE
    J Infect Public Health; 2009; 2(3):129-35. PubMed ID: 20701872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria.
    Briongos-Figuero LS; Gómez-Traveso T; Bachiller-Luque P; Domínguez-Gil González M; Gómez-Nieto A; Palacios-Martín T; González-Sagrado M; Dueñas-Laita A; Pérez-Castrillón JL
    Int J Clin Pract; 2012 Sep; 66(9):891-6. PubMed ID: 22897466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status of extended spectrum β-lactamase-producing Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis in Okinawa prefecture, Japan.
    Nakama R; Shingaki A; Miyazato H; Higa R; Nagamoto C; Hamamoto K; Ueda S; Hachiman T; Touma Y; Miyagi K; Kawahara R; Toyosato T; Hirai I
    J Infect Chemother; 2016 May; 22(5):281-6. PubMed ID: 26898665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nationwide survey of extended-spectrum {beta}-lactamase-producing Enterobacteriaceae in the French community setting.
    Arpin C; Quentin C; Grobost F; Cambau E; Robert J; Dubois V; Coulange L; André C;
    J Antimicrob Chemother; 2009 Jun; 63(6):1205-14. PubMed ID: 19329798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
    Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
    Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and antimicrobial susceptibility pattern of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the United Arab Emirates.
    Al-Zarouni M; Senok A; Rashid F; Al-Jesmi SM; Panigrahi D
    Med Princ Pract; 2008; 17(1):32-6. PubMed ID: 18059098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
    Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
    J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997-2000).
    Gales AC; Sader HS; Jones RN;
    Diagn Microbiol Infect Dis; 2002 Nov; 44(3):289-99. PubMed ID: 12493177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ongoing increasing temporal and geographical trends of the incidence of extended-spectrum beta-lactamase-producing Enterobacteriaceae infections in France, 2009 to 2013.
    Arnaud I; Maugat S; Jarlier V; Astagneau P;
    Euro Surveill; 2015; 20(36):. PubMed ID: 26536042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [THE APPLICATION OF SELECTIVE CHROMOGENIC AGAR FOR DETECTING ENTEROBACTERIA WITH PRODUCTION OF BETA-LACTAMASES].
    Korobova AG; Frolova LN; Kliasova GA
    Klin Lab Diagn; 2015 Nov; 60(11):53-7. PubMed ID: 26999867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Travel to Asia and traveller's diarrhoea with antibiotic treatment are independent risk factors for acquiring ciprofloxacin-resistant and extended spectrum β-lactamase-producing Enterobacteriaceae-a prospective cohort study.
    Reuland EA; Sonder GJ; Stolte I; Al Naiemi N; Koek A; Linde GB; van de Laar TJ; Vandenbroucke-Grauls CM; van Dam AP
    Clin Microbiol Infect; 2016 Aug; 22(8):731.e1-7. PubMed ID: 27223840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors associated with extended-spectrum β-lactamase-producing Enterobacteriaceae nosocomial bloodstream infections in a tertiary care hospital: a clinical and molecular analysis.
    Muro S; Garza-González E; Camacho-Ortiz A; González GM; Llaca-Díaz JM; Bosques F; Rositas F
    Chemotherapy; 2012; 58(3):217-24. PubMed ID: 22814216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.